Trial Outcomes & Findings for The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis (NCT NCT05356793)
NCT ID: NCT05356793
Last Updated: 2026-04-14
Results Overview
Clinical score of 0 (zero) for both Conjunctival Injection (Minimum score: 0, maximum score: 3, 0 is best outcome) and Conjunctival Discharge (minimum score: 0, maximum score 3, 0 is best outcome).
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
30 participants
Primary outcome timeframe
Day 5
Results posted on
2026-04-14
Participant Flow
March 1, 2021 to March 28, 2022, Single Private Practice Clinical Site
Participant milestones
| Measure |
Treatment
Active treatment with SCH-1, a novel anti-infective eyedrop
|
Placebo
Placebo: SCH-1 vehicle minus active components eyedrop
|
|---|---|---|
|
Overall Study
STARTED
|
16
|
14
|
|
Overall Study
COMPLETED
|
16
|
14
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Treatment
n=16 Participants
Active treatment with SCH-1
|
Placebo
n=14 Participants
Placebo: SCH-1 vehicle minus active components eyedrop
|
Total
n=30 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=16 Participants
|
0 Participants
n=14 Participants
|
0 Participants
n=30 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=16 Participants
|
8 Participants
n=14 Participants
|
10 Participants
n=30 Participants
|
|
Age, Categorical
>=65 years
|
14 Participants
n=16 Participants
|
6 Participants
n=14 Participants
|
20 Participants
n=30 Participants
|
|
Age, Continuous
|
74.2 years
STANDARD_DEVIATION 8.8 • n=16 Participants
|
66.1 years
STANDARD_DEVIATION 7.4 • n=14 Participants
|
70.4 years
STANDARD_DEVIATION 9.0 • n=30 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=16 Participants
|
8 Participants
n=14 Participants
|
21 Participants
n=30 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=16 Participants
|
6 Participants
n=14 Participants
|
9 Participants
n=30 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
United States
|
16 participants
n=16 Participants
|
14 participants
n=14 Participants
|
30 participants
n=30 Participants
|
|
Conjunctival injection score of 2 or greater
|
16 Participants
n=16 Participants
|
14 Participants
n=14 Participants
|
30 Participants
n=30 Participants
|
|
Conjunctival discharge score of 2 or greater
|
16 Participants
n=16 Participants
|
14 Participants
n=14 Participants
|
30 Participants
n=30 Participants
|
PRIMARY outcome
Timeframe: Day 5Clinical score of 0 (zero) for both Conjunctival Injection (Minimum score: 0, maximum score: 3, 0 is best outcome) and Conjunctival Discharge (minimum score: 0, maximum score 3, 0 is best outcome).
Outcome measures
| Measure |
Treatment
n=16 Participants
Active treatment with SCH-1
|
Placebo
n=14 Participants
Placebo: SCH-1 vehicle minus active components eyedrop
|
|---|---|---|
|
Complete Clinical Resolution
|
9 Participants
|
0 Participants
|
Adverse Events
Treatment
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Treatment
n=16 participants at risk
Active treatment with SCH-1
|
Placebo
n=14 participants at risk
Placebo: SCH-1 vehicle minus active components eyedrop
|
|---|---|---|
|
Eye disorders
Discomfort upon instillation of drop
|
50.0%
8/16 • Number of events 8 • 5 days
|
28.6%
4/14 • Number of events 4 • 5 days
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place